Copy of presentation given by Xceleron’s CSO, Dr Graham Lappin, at the 2012 ASCPT meeting, held at the Gaylord National Hotel & Convention Center, National Harbor, Maryland from 12 – 17th March
This talk was given as part of a workshop called “Metabolites in Safety Testing: What Have Clinical Pharmacologists MIST” on the morning of Saturday 17th March and which included speakers from the FDA and Pfizer.
The presentation gives an overview on the methods available for the identification and quantitation of metabolites to satisfy the MIST guidance, as well as describing how Accelerator Mass Spectrometry can be used as part of an overall strategy in combination with other technologies to give quantifiable measurement of metabolites in all matrices. Case studies from industry are also given as examples.
GSK publish on the use of AMS to determine the absolute bioavailability of dabrafenib, a BRAF inhibitor, in patients
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.